Analyst consensus rating
Regeneron Pharmaceuticals Analyst Rating: Buy
REGN is rated Buy by 27 analysts with a $840.43 target. As of 2026-08-19.
Direct answer
Regeneron Pharmaceuticals's consensus rating is Buy.
27 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $840.43.
Forecast evidence checked August 19, 2026.
Get free Regeneron Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $834.34
- Average price target
- $840.43
- High price target
- $1,030.00
- Low price target
- $730.00
- Low target gap
- -12.5%
- Target upside
- +0.7%
- High target gap
- +23.5%
- Target range width
- 36%
- Consensus rating
- Buy
- Analysts
- 27
- Evidence date
- August 19, 2026
- Valid through
- August 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $840.43.
How far are Regeneron Pharmaceuticals's low and high targets from the recorded price?
The low target implies -12.5%, while the high target implies +23.5%.
How many analysts are included in Regeneron Pharmaceuticals's consensus?
The verified consensus includes 27 analysts.
How is Regeneron Pharmaceuticals's target upside or downside calculated?
The average target of $840.43 is divided by the recorded price of $834.34, then one is subtracted to produce +0.7%. This does not guarantee a future return.
When was Regeneron Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-19. The dataset is valid through 2026-08-26.